Skip to main content
Premium Trial:

Request an Annual Quote

GeneArt, Boehringer Ingelheim Team on DNA-based Therapeutics

NEW YORK (GenomeWeb News) – Drug developer Boehringer Ingelheim and synthetic biology company GeneArt will collaborate to develop DNA-based pharmaceutical agents for clinical trials that both companies will market, GeneArt said today.
Under the agreement, GeneArt will use Boehringer Ingelheim’s technology to produce and purify plasmid DNA for use in research and for commercial purposes, and Boehringer Ingelheim will produce plasmids for the subsequent clinical trials and for sale globally.
Both companies will work together to distribute and market their complementary services, the Regensburg, Germany-based company said.
“The consistent production procedures” enabled by the collaboration will “help our customers to significantly shorten the time to market for new innovative DNA-based therapeutics and vaccines,” said Rolf Werner, senior VP Boehringer Ingelheim’s biopharmaceuticals division, in a statement.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.